Inhibrx Biosciences Financial Ratios
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences ratio analysis
Inhibrx Biosciences earned a net margin of -10773.5% in FY 2025, down from 843786.0% a year earlier. Return on equity reached -1752.2%, meaning Inhibrx Biosciences generated -17.52 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 12.58 versus 0.00 the year before, and the current ratio was 3.93.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Inhibrx Biosciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| P/E ratio (at fiscal year end) | — | 0.14 | — |
| Price / sales | 893.96 | 1,195.26 | — |
| Price / book | 145.40 | 1.79 | — |
| Operating margin | -10,386.5% | -165,724.0% | -12,178.9% |
| Net margin | -10,773.5% | 843,786.0% | -13,408.9% |
| Free cash flow margin | -9,986.5% | -98,503.0% | -10,994.6% |
| Return on equity (ROE) | -1,752.2% | 1,263.3% | -554.8% |
| Return on assets (ROA) | -95.6% | 933.6% | -78.4% |
| Debt / equity | 12.58 | 0.00 | 4.76 |
| Current ratio | 3.93 | 3.94 | 5.25 |
| Revenue growth | 550.0% | -88.9% | — |
| EPS growth | -108.0% | — | — |